Filing Analysis
Artiva Biotherapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 10, 2026.
Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results is included as Exhibit 99.1.
- The company is classified as an emerging growth company.
Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective February 18, 2026. Mr. Huston brings over 30 years of experience from major biotech and pharma companies, including Galapagos NV and Kite Pharma.
Key Facts
- Thad Huston (age 56) appointed as CFO effective February 18, 2026.
- Annual base salary set at $540,000 with a discretionary annual cash bonus target of 40%.
- Granted 220,000 restricted stock units (RSUs) as an inducement award, vesting over four years.
- Huston previously served as CFO and COO at Galapagos NV (2023-2025) and VP of Finance at Kite Pharma (2021-2023).
- Severance package includes 9 months of salary and COBRA for non-change-of-control termination, increasing to 12 months plus full bonus and 100% equity acceleration upon a change of control.
Artiva Biotherapeutics appointed Elaine Sorg as a Class I director effective February 18, 2026, with her term expiring at the 2028 annual meeting. Ms. Sorg is a veteran pharmaceutical executive with 35+ years of experience including senior leadership at AbbVie and Eli Lilly. This is a routine board appointment with standard non-employee director compensation.
Key Facts
- Elaine Sorg appointed as Class I director on February 18, 2026, term expires at 2028 annual meeting
- 35+ years pharma experience; formerly SVP at AbbVie and President of AbbVie's U.S. commercial operations (Nov 2020 - Jan 2024)
- Currently a director of CSL Limited (global biopharma), Senior Advisor at Boston Consulting Group (since May 2024), and member of Galapagos Scientific Strategy Board (since Oct 2025)
- Annual cash retainer of $40,000 for board service
- Initial option grant of 27,500 shares (1/3 vested immediately, remainder monthly over 2 years)
- Automatic annual option grants of 13,750 shares vesting over 1 year
- All options vest in full upon a change in control
- No related-party transactions requiring disclosure under Item 404(a) of Reg S-K
- No arrangements or understandings with any person regarding her selection as director